摘要
目的:评价外周血CD14+单核细胞人类白细胞DR抗原(HLA-DR/CD14+)和C-反应蛋白(CRP)对脓毒症患者预后的判断价值和临床意义。方法:选择入住ICU的脓毒症患者,治疗前测定其外周血HLA-DR/CD14+及CRP、进行APACHEⅡ评分和Marshall评分,观察追踪28天,根据其预后将患者分为存活组和死亡组,分析2组的参数差异,评估参数与患者预后的关系。结果:本研究共入选脓毒症患者21例,12例存活,9例死亡。存活组患者年龄为(65.67±17.15)岁明显低于死亡组的(71.78±8.87)岁(P<0.05);存活组患者HLA-DR/CD14+水平为(28.9±16.1)%明显高于死亡组的(18.7±12.7)%(P<0.05);存活组患者CRP水平为(56.1±18.7)mg/L明显低于死亡组的(91.1±26.3)mg/L(P<0.05)。结论:脓毒症患者的免疫状态与其预后有关,HLA-DR/CD14+和CRP水平对预后判定具有一定的临床价值。
Objective:To investigate the clinical value of CD14+ monocyte human leukocyte antigen DR(HLA-DR/CD14+)and C-reactive protein(CRP)on prognosis of patients with sepsis.Methods:Patients with sepsis were enrolled in this clinical trial.According the prognosis,the patients were divided into groups.Flow cytometry application was used to measure the levels of HLA-DR/CD14+ and CRP was measured at the same time.Results:Twenty-one patients were enrolled into this clinical trial,12 patients were survived and 9 patients were died.In survival group the age(65.67±17.15)was lower than that in death group(71.78±8.87),P〈0.05.The levels of HLA-DR/CD14+ in survival group[(28.9±16.1)%]were higher than that in death group[(18.7±12.7)%],P〈0.05.The levels of CRP in survival group[(56.1±18.7)mg/L]were lower than that in death group[(91.1±26.3)mg/L],P〈0.05.Conclusion:HLA-DR/CD14+ and CRP are valuable in predicting the prognosis of patients with sepsis.
出处
《华西医学》
CAS
2008年第4期737-738,共2页
West China Medical Journal